Isolation of adipose-derived mesenchymal stromal cells expressing soluble forms of GAS1 and PTEN for experimental cell therapy for glioblastoma.
Tovar-Medina G., Florán-Hernández CD., Avalos-Fuentes JA., Rodríguez-Cruz F., Segovia J.
Animal Study, published in Cytotherapy (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cytotherapy (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42561643
- DOI
- 10.1016/j.jcyt.2026.102927
Abstract (original English)
Background aims Glioblastoma is the most frequent primary brain tumor, and its current treatment mainly prolongs survival, highlighting the need for more effective second-line therapies to improve patient prognosis. Stem cells represent a promising platform for developing cell-based therapies due to their biological characteristics, which enable the delivery of antitumoral agents. Still, there are some limitations, such as invasive delivery methods to overcome the blood-brain barrier, and the need for repeated administration, among others. Here, we propose a cellular therapy based on a stable adipose-derived mesenchymal stem cell line (Ad-MSC) genetically engineered to express the therapeutic genes tGAS1 and PTEN-L, tumor suppressors that interfere with signaling pathways associated with glioblastoma growth and survival, under tetracycline regulation. Methods The therapeutic strategy was evaluated in both in vitro and in vivo glioblastoma models, with engineered Ad-MSCs administered intranasally in vivo to target glioblastoma tumors. Results The therapeutic system showed tropism toward intracranially implanted tumors, inducible expression and release of tGAS1 and PTEN-L, and a significant reduction in tumor volume (p Conclusions Thus, our data indicates that intranasal administration of Ad-MSC expressing inducible tGAS1 and PTEN-L, represents a promising alternative to overcome
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.